Evidence map›Paper›PMID 36014345›Full record

ArticleMolecules (Basel, Switzerland)2022

Meenakshi Gupta, Shaikh Maryam Ghufran, Tasneem Kausar, Rafat Ali, Subhrajit Biswas, Shahid M Nayeem, Romana Ishrat, Sher Ali, Ajaz Ahmad, Irfan A Rather and 1 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Meenakshi GuptaAmity Institute of Pharmacy, Amity University, Noida 201313, Uttar Pradesh, India.
Shaikh Maryam GhufranAmity Institute of Molecular Medicine & Stem Cell Research, Amity University, Noida 201313, Uttar Pradesh, India.
Tasneem KausarDepartment of Chemistry, Aligarh Muslim University, Aligarh 202001, Uttar Pradesh, India.
Rafat AliCentre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi 110025, Uttar Pradesh, India.
Subhrajit BiswasAmity Institute of Molecular Medicine & Stem Cell Research, Amity University, Noida 201313, Uttar Pradesh, India.ORCID 0000-0001-5649-364X
Shahid M NayeemDepartment of Chemistry, Aligarh Muslim University, Aligarh 202001, Uttar Pradesh, India.
Romana IshratCentre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi 110025, Uttar Pradesh, India.
Sher AliCentre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi 110025, Uttar Pradesh, India.
Ajaz AhmadDepartment of Clinical Pharmacy, College of Pharmacy and King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.
Irfan A RatherDepartment of Applied Microbiology and Biotechnology, Yeungnam University, Gyeongsan 38541, Korea.ORCID 0000-0003-2752-0519
Maryam SarwatAmity Institute of Pharmacy, Amity University, Noida 201313, Uttar Pradesh, India.ORCID 0000-0003-3972-3321
Amity University · INJamia Millia Islamia · INAligarh Muslim University · INKing Saud University · SAYeungnam University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An ancient saffron-based polyherbal formulation, Dawa-ul-Kurkum (DuK), has been used to treat liver ailments and other diseases and was recently evaluated for its anticancer potential against hepatocellular carcinoma (HCC) by our research team. To gain further insight into the lead molecule of DuK, we selected ten active constituents belonging to its seven herbal constituents (crocin, crocetin, safranal, jatamansone, isovaleric acid, cinnamaldehyde, coumaric acid, citral, guggulsterone and dehydrocostus lactone). We docked them with 32 prominent proteins that play important roles in the development, progression and suppression of HCC and those involved in endoplasmic reticulum (ER) stress to identify the binding interactions between them. Three reference drugs for HCC (sorafenib, regorafenib, and nivolumab) were also examined for comparison. The in silico studies revealed that, out of the ten compounds, three of them-

Indexed as

Carcinoma, HepatocellularCrocusLiver NeoplasmsPregnenedionesHumanspregna-4,17-diene-3,16-dionePregnenedionesDawa-ul-KurkumER stressguggulsteronehepatocellular carcinomaMD simulationmolecular docking studies

Identifiers

PMID36014345
PMCPMC9413334
OpenAlexW4291017386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.